No Cover Image

Journal article 661 views 166 downloads

Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK

Natasha Shrikrishnapalasuriyar, Ayesha Shaikh, Aliya Mohd Ruslan, Giselle Sharaf, Maneesh Udiawar, David E. Price, Jeffrey Stephens Orcid Logo

Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Volume: 14, Issue: 3, Pages: 237 - 239

Swansea University Author: Jeffrey Stephens Orcid Logo

  • 53936.pdf

    PDF | Accepted Manuscript

    Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).

    Download (123.77KB)

Check full text

DOI (Published version): 10.1016/j.dsx.2020.03.007

Published in: Diabetes & Metabolic Syndrome: Clinical Research & Reviews
ISSN: 1871-4021
Published: Elsevier BV 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa53936
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2020-04-13T19:49:42Z
last_indexed 2020-07-07T13:16:57Z
id cronfa53936
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-07-07T07:10:51.9014567</datestamp><bib-version>v2</bib-version><id>53936</id><entry>2020-04-13</entry><title>Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK</title><swanseaauthors><author><sid>5219d126f97f8f884bdb622099bd41de</sid><ORCID>0000-0003-2228-086X</ORCID><firstname>Jeffrey</firstname><surname>Stephens</surname><name>Jeffrey Stephens</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-04-13</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews</journal><volume>14</volume><journalNumber>3</journalNumber><paginationStart>237</paginationStart><paginationEnd>239</paginationEnd><publisher>Elsevier BV</publisher><issnPrint>1871-4021</issnPrint><keywords>Dapagliflozin; SGLT2 inhibitor; HbA1c; Cardiovascular</keywords><publishedDay>1</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-05-01</publishedDate><doi>10.1016/j.dsx.2020.03.007</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-07-07T07:10:51.9014567</lastEdited><Created>2020-04-13T17:25:56.2543825</Created><authors><author><firstname>Natasha</firstname><surname>Shrikrishnapalasuriyar</surname><order>1</order></author><author><firstname>Ayesha</firstname><surname>Shaikh</surname><order>2</order></author><author><firstname>Aliya Mohd</firstname><surname>Ruslan</surname><order>3</order></author><author><firstname>Giselle</firstname><surname>Sharaf</surname><order>4</order></author><author><firstname>Maneesh</firstname><surname>Udiawar</surname><order>5</order></author><author><firstname>David E.</firstname><surname>Price</surname><order>6</order></author><author><firstname>Jeffrey</firstname><surname>Stephens</surname><orcid>0000-0003-2228-086X</orcid><order>7</order></author></authors><documents><document><filename>53936__17057__9bcd8d0946b641a0a69b011ea03e94e1.pdf</filename><originalFilename>53936.pdf</originalFilename><uploaded>2020-04-14T09:19:39.8198441</uploaded><type>Output</type><contentLength>126736</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2021-03-26T00:00:00.0000000</embargoDate><documentNotes>Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2020-07-07T07:10:51.9014567 v2 53936 2020-04-13 Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK 5219d126f97f8f884bdb622099bd41de 0000-0003-2228-086X Jeffrey Stephens Jeffrey Stephens true false 2020-04-13 BMS Journal Article Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14 3 237 239 Elsevier BV 1871-4021 Dapagliflozin; SGLT2 inhibitor; HbA1c; Cardiovascular 1 5 2020 2020-05-01 10.1016/j.dsx.2020.03.007 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2020-07-07T07:10:51.9014567 2020-04-13T17:25:56.2543825 Natasha Shrikrishnapalasuriyar 1 Ayesha Shaikh 2 Aliya Mohd Ruslan 3 Giselle Sharaf 4 Maneesh Udiawar 5 David E. Price 6 Jeffrey Stephens 0000-0003-2228-086X 7 53936__17057__9bcd8d0946b641a0a69b011ea03e94e1.pdf 53936.pdf 2020-04-14T09:19:39.8198441 Output 126736 application/pdf Accepted Manuscript true 2021-03-26T00:00:00.0000000 Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND). true eng
title Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
spellingShingle Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
Jeffrey Stephens
title_short Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
title_full Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
title_fullStr Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
title_full_unstemmed Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
title_sort Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
author_id_str_mv 5219d126f97f8f884bdb622099bd41de
author_id_fullname_str_mv 5219d126f97f8f884bdb622099bd41de_***_Jeffrey Stephens
author Jeffrey Stephens
author2 Natasha Shrikrishnapalasuriyar
Ayesha Shaikh
Aliya Mohd Ruslan
Giselle Sharaf
Maneesh Udiawar
David E. Price
Jeffrey Stephens
format Journal article
container_title Diabetes & Metabolic Syndrome: Clinical Research & Reviews
container_volume 14
container_issue 3
container_start_page 237
publishDate 2020
institution Swansea University
issn 1871-4021
doi_str_mv 10.1016/j.dsx.2020.03.007
publisher Elsevier BV
document_store_str 1
active_str 0
published_date 2020-05-01T04:07:11Z
_version_ 1763753518716420096
score 11.017776

Similar Items